1. TNF receptor-related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF-κB- inducing kinase-mediated hepatocyte transdifferentiation.
   Shiode Y, Kodama T, Shigeno S, Murai K, Tanaka S, Newberg JY, Kondo J, Kobayashi S, Yamada R, Hikita H, Sakamori R, Suemizu H, Tatsumi T, Eguchi H, Jenkins NA, Copeland NG, Takehara T.
   Hepatology. 2022 Jan 7. Online ahead of print.
   
2. Capsid Allosteric Modulators Enhance the Innate Immune Response in Hepatitis B Virus-Infected Hepatocytes During Interferon Administration.
   Fukutomi K, Hikita H, Murai K, Nakabori T, Shimoda A, Fukuoka M, Yamai T, Higuchi Y, Miyakawa K, Suemizu H, Ryo A, Yamada R, Kodama T, Sakamori R, Tatsumi T, Takehara T.
   Hepatol Commun. 2022 Feb;6(2):281-296.
   
3. Activation of p53 After Irradiation Impairs the Regenerative Capacity of the Mouse Liver.
   Urabe M, Hikita H, Saito Y, Kudo S, Fukumoto K, Mizutani N, Myojin Y, Doi A, Sato K, Sakane S, Makino Y, Kodama T, Sakamori R, Tatsumi T, Takehara T.
   Hepatol Commun. 2022 Feb;6(2):411-422.
   
4. Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination.
   Myojin Y, Hikita H, Tahata Y, Doi A, Kato S, Sasaki Y, Shirai K, Sakane S, Yamada R, Kodama T, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Ohkawa K, Hijioka T, Fukui H, Doi Y, Yamada Y, Yakushijin T, Mita E, Sakamori R, Tatsumi T, Takehara T.
   Aliment Pharmacol Ther. 2022 Feb;55(4):422-433.
   
5. An improved TK-NOG mouse as a novel platform for humanized liver that overcomes limitations in both male and female animals.
   Uehara S, Higuchi Y, Yoneda N, Kawai K, Yamamoto M, Kamimura H, Iida Y, Oshimura M, Kazuki Y, Yamazaki H, Hikita H, Takehara T, Suemizu H.
   Drug Metab Pharmacokinet. 2022 Feb;42:100410.
   
6. Liver- related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis.
   Tahata Y, Hikita H, Mochida S, Enomoto N, Kawada N, Kurosaki M, Ido A, Miki D, Yoshiji H, Takikawa Y, Sakamori R, Hiasa Y, Nakao K, Kato N, Ueno Y, Yatsuhashi H, Itoh Y, Tateishi R, Suda G, Takami T, Nakamoto Y, Asahina Y, Matsuura K, Yamashita T, Kanto T, Akuta N, Terai S, Shimizu M, Sobue S, Miyaki T, Moriuchi A, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T.
   J Gastroenterol. 2022 Feb;57(2):120-132.
   
7. The absence of warfarin treatment and situs inversus are associated with the occurrence of hepatocellular carcinoma after Fontan surgery.
   Sakamori R, Yamada R, Tahata Y, Kodama T, Hikita H, Tatsumi T, Yamada T, Takehara T.
   J Gastroenterol. 2022 Feb;57(2):111-119.
   
8. Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy.
   Myojin Y, Kodama T, Sakamori R, Maesaka K, Matsumae T, Sawai Y, Imai Y, Ohkawa K, Miyazaki M, Tanaka S, Mita E, Tawara S, Yakushijin T, Nozaki Y, Hagiwara H, Tahata Y, Yamada R, Hikita H, Tatsumi T, Takehara T.
   Cancers (Basel). 2022 Feb 10;14(4):883.
   
9. Geriatric nutritional risk index as a prognostic indicator in elderly patients with early colorectal cancer undergoing endoscopic submucosal dissection.
   Kato M, Hayashi Y, Fukuda H, Yamaguchi S, Inoue T, Ogiyama H, Kitamura S, Komori M, Yamamoto K, Yamamoto M, Nagai K, Nakahara M, Egawa S, Yamada T, Sasakawa A, Kizu T, Nishiyama O, Shichijo S, Yoshii S, Tsujii Y, Shinzaki S, Iijima H, Takehara T.
   Dig Endosc. 2022 Mar;34(3):569-578.
   
10. The First Transileocolic Obliteration for Refractory Esophageal Varices: A Case Report and Review of the Literature.
    Fujii Y, Sakamori R, Yamada R, Yoshioka T, Kodama T, Shigekawa M, Hikita H, Tanaka S, Ishida H, Mita E, Hongyo H, Higashihara H, Noda T, Eguchi H, Tatsumi T, Takehara T.
    Intern Med. 2022 Mar 15;61(6):835-839.
    
11. Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy.
    Maesaka K, Sakamori R, Yamada R, Tahata Y, Imai Y, Ohkawa K, Miyazaki M, Mita E, Ito T, Hagiwara H, Yakushijin T, Kodama T, Hikita H, Tatsumi T, Takehara T.
    Hepatol Res. 2022 Mar;52(3):298-307.
    
12. Elderly onset age is associated with low efficacy of first anti-tumor necrosis factor treatment in patients with inflammatory bowel disease.
    Amano T, Shinzaki S, Asakura A, Tashiro T, Tani M, Otake Y, Yoshihara T, Iwatani S, Yamada T, Sakakibara Y, Osugi N, Ishii S, Egawa S, Araki M, Arimoto Y, Nakahara M, Murayama Y, Kobayashi I, Kinoshita K, Ogawa H, Hiyama S, Shibukawa N, Komori M, Okuda Y, Kizu T, Yoshii S, Tsujii Y, Hayashi Y, Inoue T, Iijima H, Takehara T.
    Sci Rep. 2022 Mar 29;12(1):5324.
    
13. Prediction Model for Intrahepatic Distant Recurrence After Radiofrequency Ablation for Primary Hepatocellular Carcinoma 2 cm or Smaller.
    Takigawa A, Sakamori R, Tahata Y, Yoshioka T, Yamada R, Kodama T, Hikita H, Yakushijin T, Ohkawa K, Hiramatsu N, Mita E, Hagiwara H, Ito T, Imai Y, Tatsumi T, Takehara T.
    Dig Dis Sci. 2022 Mar 30. Online ahead of print.
    
14. Hepatocellular Carcinoma in a Patient with Tetralogy of Fallot: A Case Report and Literature Review.
    Hyun Sung J, Sakamori R, Yamada R, Yoshioka T, Sakane S, Tahata Y, Shigekawa M, Kodama T, Hikita H, Tatsumi T, Takehara T.
    Intern Med. 2022 May 1;61(9):1361-1365.
    
15. The degree of mucosal atrophy is associated with post-endoscopic submucosal dissection bleeding in early gastric cancer.
    Hayashi Y, Hatta W, Tsuji Y, Yoshio T, Yabuuchi Y, Hoteya S, Tsuji S, Nagami Y, Hikichi T, Kobayashi M, Morita Y, Sumiyoshi T, Iguchi M, Tomida H, Inoue T, Mikami T, Hasatani K, Nishikawa J, Matsumura T, Nebiki H, Nakamatsu D, Ohnita K, Suzuki H, Ueyama H, Sugimoto M, Yamaguchi S, Michida T, Yada T, Asahina Y, Narasaka T, Kuribayashi S, Kiyotoki S, Mabe K, Miyake A, Fujishiro M, Masamune A, Takehara T.
    J Gastroenterol Hepatol. 2022 May;37(5):870-877.
    
16. Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma.
    Murai H, Kodama T, Maesaka K, Tange S, Motooka D, Suzuki Y, Shigematsu Y, Inamura K, Mise Y, Saiura A, Ono Y, Takahashi Y, Kawasaki Y, Iino S, Kobayashi S, Idogawa M, Tokino T, Hashidate-Yoshida T, Shindou H, Miyazaki M, Imai Y, Tanaka S, Mita E, Ohkawa K, Hikita H, Sakamori R, Tatsumi T, Eguchi H, Morii E, Takehara T.
    Hepatology. 2022 May 14. Online ahead of print.
    
17. "Stardust" gastric mucosa in the course of immune checkpoint inhibitor-associated gastritis.
    Okamoto A, Yoshii S, Tsujii Y, Hayashi Y, Shinzaki S, Takehara T.
    Am J Gastroenterol. 2022 May 25. Online ahead of print.
    
18. Initial drainage-related prognostic factors for perihilar cholangiocarcinoma: A single-center retrospective study.
    Sato K, Shigekawa M, Kozumi K, Okabe J, Sato Y, Tamura T, Yoshioka T, Sakamori R, Iwagami Y, Yamada D, Tomimaru Y, Noda T, Takahashi H, Kobayashi S, Eguchi H, Tatsumi T, Takehara T.
    DEN open. 2022 May 22;3(1):e127.
    
19. Prognostic impact of worsening of esophageal varices after balloon-occluded retrograde transvenous obliteration.
    Shinkai K, Sakamori R, Yamada R, Tahata Y, Nozaki Y, Matsumoto K, Tawara S, Fukuda K, Yoshida Y, Tanaka S, Ito T, Doi Y, Iio S, Sakakibara M, Nakanishi F, Kodama T, Hikita H, Tatsumi T, Takehara T.
    J Gastroenterol Hepatol. 2022 Jun;37(6):1148-1155.
    
20. Cerebellopontine angle metastasis of a neuroendocrine tumor mimicking vestibular schwannoma: A case report.
    Yamada S, Kijima N, Kinoshita M, Shinzaki S, Sato K, Kido K, Hirayama R, Kagawa N, Takehara T, Morii E, Kishima H.
    Surg Neurol Int. 2022 Jun 23;13:264.
    
21. Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma.
    Maesaka K, Sakamori R, Yamada R, Doi A, Tahata Y, Miyazaki M, Ohkawa K, Mita E, Iio S, Nozaki Y, Yakushijin T, Imai Y, Kodama T, Hikita H, Tatsumi T, Takehara T.
    Hepatol Res. 2022 Jul;52(7):630-640.
    
22. Lysophosphatidylserines derived from microbiota in Crohn's disease elicit pathological Th1 response.
    Otake-Kasamoto Y, Kayama H, Kishikawa T, Shinzaki S, Tashiro T, Amano T, Tani M, Yoshihara T, Li B, Tani H, Liu L, Hayashi A, Okuzaki D, Motooka D, Nakamura S, Okada Y, Iijima H, Takeda K, Takehara T.
    J Exp Med. 2022 Jul 4;219(7):e20211291.
    
23. Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients.
    Shirai K, Hikita H, Sakane S, Narumi R, Adachi J, Doi A, Tanaka S, Tahata Y, Yamada R, Kodama T, Sakamori R, Tatsumi T, Mita E, Tomonaga T, Takehara T.
    PLoS One. 2022 Jul 7;17(7):e0271020.
    
24. Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy.
    Matsumae T, Kodama T, Myojin Y, Maesaka K, Sakamori R, Takuwa A, Oku K, Motooka D, Sawai Y, Oshita M, Nakabori T, Ohkawa K, Miyazaki M, Tanaka S, Mita E, Tawara S, Yakushijin T, Nozaki Y, Hagiwara H, Tahata Y, Yamada R, Hikita H, Tatsumi T, Takehara T.
    Cancers (Basel). 2022 Jul 11;14(14):3367.
    
25. Exacerbation of non-steroidal anti- inflammatory drug-induced enteropathy in C-C chemokine receptor type 7-deficient mice.
    Yamaguchi T, Iijima H, Yoshihara T, Tani M, Otake Y, Iwatani S, Amano T, Tashiro T, Kurahashi T, Inoue T, Tsujii Y, Hayashi Y, Inoue T, Motooka D, Nakamura S, Shinzaki S, Takehara T.
    J Gastroenterol Hepatol. 2022 Aug;37(8):1561-1570.
    
26. Constitutive Activation of the Tumor Suppressor p53 in Hepatocytes Paradoxically Promotes Non-Cell Autonomous Liver Carcinogenesis.
    Makino Y, Hikita H, Fukumoto K, Sung JH, Sakano Y, Murai K, Sakane S, Kodama T, Sakamori R, Kondo J, Kobayashi S, Tatsumi T, Takehara T.
    Cancer Res. 2022 Aug 16;82(16):2860-2873.
    
27. Ulcerative colitis- associated flat-appearing rectal cancer with submucosal extension.
    Sakamoto T, Yoshii S, Tsujii Y, Shinzaki S, Takehara T.
    Gastrointest Endosc. 2022 Aug 24:S0016-5107(22)01936-8.
    
28. Endoscopic submucosal dissection in the right lateral position for early gastric cancer in the fornix.
    Fukuda H, Tsujii Y, Kato M, Hayashi Y, Takehara T.
    VideoGIE. 2022 Aug 5;7(9):327-330.
    
29. No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapy.
    Korenaga M, Murata K, Izumi N, Tamaki N, Yokosuka O, Takehara T, Sakamoto N, Suda G, Nishiguchi S, Enomoto H, Ikeda F, Yanase M, Toyoda H, Genda T, Umemura T, Yatsuhashi H, Yamasaki K, Ide T, Toda N, Kanda T, Nirei K, Ueno Y, Haga H, Nishigaki Y, Nakane K, Omata M, Mochizuki H, Aoki Y, Imamura M, Kanto T, Mizokami M.
    Glob Health Med. 2022 Aug 31;4(4):216-224.
    
30. Gastric carcinoma with lymphoid stroma partially differentiated into squamous cell carcinoma.
    Inoue T, Hayashi Y, Tsujii Y, Yoshii S, Takehara T.
    Gastrointest Endosc. 2022 Sep;96(3):564-565.
    
31. Inhibition of nonhomologous end joining-mediated DNA repair enhances anti-HBV CRISPR therapy.
    Murai K, Kodama T, Hikita H, Shimoda A, Fukuoka M, Fukutomi K, Shigeno S, Shiode Y, Motooka D, Higuchi Y, Miyakawa K, Suemizu H, Ryo A, Tahata Y, Makino Y, Yamada R, Sakamori R, Tatsumi T, Takehara T.
    Hepatol Commun. 2022 Sep;6(9):2474-2487.
    
32. Clinical and Histopathological Features of the Differentiated Type of Early Gastric Cancer with an Unclear Lateral Demarcation.
    Nagai K, Hayashi Y, Uema R, Inoue T, Kimura K, Sakatani A, Yoshii S, Tsujii Y, Shinzaki S, Iijima H, Takehara T.
    Digestion. 2022;103(5):347-356.
    
33. PTX3 Is an Adipose Tissue- Related Serum Marker for Pancreatic Cancer Cachexia Predicting Subsequent Muscle Mass and Visceral Fat Loss.
    Sato K, Hikita H, Shigekawa M, Kato S, Sasaki Y, Shinkai K, Fukuoka M, Kudo S, Sato Y, Fukumoto K, Shirai K, Myojin Y, Sakane S, Murai K, Yoshioka T, Nishio A, Kodama T, Sakamori R, Tatsumi T, Takehara T.
    Cancer Sci. 2022 Sep 8. Online ahead of print.
    
34. STAT3 is Activated by CTGF-mediated Tumor-stroma Cross Talk to Promote HCC Progression.
    Makino Y, Hikita H, Kato S, Sugiyama M, Shigekawa M, Sakamoto T, Sasaki Y, Murai K, Sakane S, Kodama T, Sakamori R, Kobayashi S, Eguchi H, Takemura N, Kokudo N, Yokoi H, Mukoyama M, Tatsumi T, Takehara T.
    Cell Mol Gastroenterol Hepatol. 2022 Sep 20. Online ahead of print.
    
35. Duodenal diverticulum metastasis from pulmonary squamous cell carcinoma diagnosed by EUS-FNA.
    Sunaga K, Yoshioka T, Shigekawa M, Sato K, Sakamori R, Tatsumi T, Ukon K, Morii E, Takehara T.
    Clin J Gastroenterol. 2022 Sep 29. Online ahead of print.
    
36. Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis.
    Tahata Y, Sakamori R, Yamada R, Kodama T, Hikita H, Nozaki Y, Oshita M, Hiramatsu N, Miyazaki M, Mita E, Yamamoto K, Ohkawa K, Kaneko A, Ito T, Doi Y, Yakushijin T, Hijioka T, Fukui H, Imanaka K, Yoshida Y, Yamada Y, Tatsumi T, Takehara T.
    Hepatol Res. 2022 Oct;52(10):824-832.
    
37. Sofosbuvir-velpatasvir in adults with hepatitis C virus infection and compensated cirrhosis in Japan.
    Takehara T, Izumi N, Mochida S, Genda T, Fujiyama S, Notsumata K, Tamori A, Suzuki F, Suri V, Mercier RC, Matsuda T, Matsuda K, Kato N, Chayama K, Kumada H.
    Hepatol Res. 2022 Oct;52(10):833-840.
    
38. Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy.
    Kawagishi N, Suda G, Sakamori R, Matsui T, Onozawa M, Yang Z, Yoshida S, Ohara M, Kimura M, Kubo A, Maehara O, Fu Q, Hosoda S, Tokuchi Y, Suzuki K, Nakai M, Sho T, Morikawa K, Natsuizaka M, Ogawa K, Sakai H, Ohnishi S, Baba M, Takehara T, Sakamoto N.
    Sci Rep. 2022 Oct 7;12(1):16800.
    
39. Prokaryotic and viral genomes recovered from 787 Japanese gut metagenomes revealed microbial features linked to diets, populations, and diseases.
    Tomofuji Y, Kishikawa T, Maeda Y, Ogawa K, Otake-Kasamoto Y, Kawabata S, Nii T, Okuno T, Oguro-Igashira E, Kinoshita M, Takagaki M, Oyama N, Todo K, Yamamoto K, Sonehara K, Yagita M, Hosokawa A, Motooka D, Matsumoto Y, Matsuoka H, Yoshimura M, Ohshima S, Shinzaki S, Nakamura S, Iijima H, Inohara H, Kishima H, Takehara T, Mochizuki H, Takeda K, Kumanogoh A, Okada Y.
    Cell Genom. 2022 Nov 30;2(12):100219.
    
40. Ulcerative colitis-associated flat-appearing rectal cancer with submucosal extension.
    Sakamoto T, Yoshii S, Tsujii Y, Shinzaki S, Takehara T.
    Gastrointest Endosc. 2022 Dec;96(6):1085-1086.
    
41. Pentraxin 3 is an adipose tissue-related serum marker for pancreatic cancer cachexia predicting subsequent muscle mass and visceral fat loss.
    Sato K, Hikita H, Shigekawa M, Kato S, Sasaki Y, Shinkai K, Fukuoka M, Kudo S, Sato Y, Fukumoto K, Shirai K, Myojin Y, Sakane S, Murai K, Yoshioka T, Nishio A, Kodama T, Sakamori R, Tatsumi T, Takehara T.
    Cancer Sci. 2022 Dec;113(12):4311-4326.
    
42. Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis.
    Shirai K, Hikita H, Sakamori R, Doi A, Tahata Y, Sakane S, Kamada Y, Murai K, Nishio A, Yamada R, Kodama T, Nozaki Y, Kakita N, Ishida H, Nakanishi F, Morishita N, Imanaka K, Sakakibara M, Tatsumi T, Miyoshi E, Takehara T.
    PLoS One. 2022 Dec 21;17(12):e0279416.
    
43. Influence of hospital volume on bleeding after endoscopic submucosal dissection for early gastric cancer in Japan: a multicenter propensity score-matched analysis.
    Yabuuchi Y, Hatta W, Tsuji Y, Yoshio T, Kakushima N, Hoteya S, Doyama H, Nagami Y, Hikichi T, Kobayashi M, Morita Y, Sumiyoshi T, Iguchi M, Tomida H, Inoue T, Mikami T, Hasatani K, Nishikawa J, Matsumura T, Nebiki H, Nakamatsu D, Ohnita K, Suzuki H, Ueyama H, Hayashi Y, Sugimoto M, Yamaguchi S, Michida T, Yada T, Asahina Y, Narasaka T, Kuribayashi S, Kiyotoki S, Mabe K, Fujishiro M, Masamune A, Ono H.
    Surg Endosc. 2022 Jun;36(6):4004-4013.
    
44. Antithrombotics increase bleeding after endoscopic submucosal dissection for gastric cancer: Nationwide propensity score analysis.
    Nagami Y, Hatta W, Tsuji Y, Yoshio T, Kakushima N, Hoteya S, Tsuji S, Fukunaga S, Hikichi T, Kobayashi M, Morita Y, Sumiyoshi T, Iguchi M, Tomida H, Inoue T, Mikami T, Hasatani K, Nishikawa J, Matsumura T, Nebiki H, Nakamatsu D, Ohnita K, Suzuki H, Ueyama H, Hayashi Y, Yoshida H, Fujishiro M, Masamune A, Fujiwara Y.
    Dig Endosc. 2022 Jul;34(5):974-983.
    
45. Characteristics of colorectal neuroendocrine tumors in patients prospectively enrolled in a Japanese multicenter study: a first report from the C-NET STUDY.
    Sekiguchi M, Hotta K, Takeuchi Y, Tanaka S, Yamamoto H, Shinmura K, Harada K, Uraoka T, Hisabe T, Sano Y, Kondo H, Horimatsu T, Kikuchi H, Kawamura T, Nagata S, Yamamoto K, Tajika M, Tsuji S, Kusaka T, Okuyama Y, Yoshida N, Moriyama T, Hasebe A, So S, Kobara H, Kashida H, Miyanaga R, Kato S, Hayashi Y, Sada M, Fukuzawa M, Kato H, Takayama T, Konishi J, Matsushita HO, Narasaka T, Ohata K, Togashi K, Nakamura H, Moriichi K, Oda Y, Kanda N, Kuwai T, Terai S, Sanomura M, Kitamura S, Miyamoto H, Kiriyama S, Mizuno C, Saito Y, Sekine S, Ito S, Nakahira H, Oka S, Hayashi Y, Yoshimura K, Ishikawa H, Matsuda T; C-NET STUDY Group.
    J Gastroenterol. 2022 Aug;57(8):547-558
    
46. Bleeding following Endoscopic Submucosal Dissection for Early Gastric Cancer in Surgically Altered Stomach.
    Odagiri H, Hatta W, Tsuji Y, Yoshio T, Yabuuchi Y, Kikuchi D, Tsuji S, Nagami Y, Hikichi T, Kobayashi M, Morita Y, Sumiyoshi T, Iguchi M, Tomida H, Inoue T, Mikami T, Hasatani K, Nishikawa J, Matsumura T, Nebiki H, Nakamatsu D, Ohnita K, Suzuki H, Ueyama H, Hayashi Y, Sugimoto M, Yamaguchi S, Michida T, Yada T, Asahina Y, Narasaka T, Kuribayashi S, Kiyotoki S, Mabe K, Fujishiro M, Masamune A, Hoteya S.
    Digestion. 2022. in press.
    

邦論文

1. 食道癌術後後縦隔経路再建胃管癌に対する胸腔鏡・内視鏡合同手術の経験
   青山　修宇、田中　晃司、山下　公太郎、牧野　知紀、辻井　芳樹、西塔　拓郎、山本　和義、高橋　剛、黒川　幸典、中島　清一、竹原　徹郎、江口　英利、土岐　祐一郎
   癌と化学療法2022年49巻13号 p.1911-1913

患者の皆様へ

学生・研修医のみなさまへ

阪大消化器内科のご紹介